

NEWSLETTER 61 - August 2020

Covid-19 in Pregnancy Study

As most of you are aware, the Covid-19 paper presenting study results from 1st March to 14th April was published in the BMJ in June (please see link below). We would like to thank all our UKOSS and Covid-19 reporters for all your hard work providing us with the data so promptly. Without your support we would not have been able to undertake such a rapid analysis of the data.

Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study: https://www.bmj.com/content/bmj/369/bmj.m2107.full.pdf



The UKOSS team would like to say

a big Thank you to you all!

Non-Covid UKOSS studies – change to study end dates

This is a reminder that due to the Covid-19 pandemic, the UKOSS Steering Committee have agreed to extend all studies that were scheduled to end this year by six months. Please note that the new end dates for the affected studies are as follows:-

Study	End Date
Hyponatraemia	30/09/2020
DKA	30/09/2020
Cirrhosis	30/11/2020
Antithrombin/Protein C Deficiency	31/12/2020
EPPROM	28/02/2021

Returning data collection forms for non-Covid UKOSS studies

Historically, following a case report we have sent a paper data collection form to the UKOSS reporter to complete and also return via post. However, we were required to adapt our data collection process for the Covid-19 study to ensure that we received the data as soon as possible to allow for weekly data analysis for the RCOG/ RCM/Departments of Health and WHO. It was also necessary to ensure that the study could run smoothly whilst the UKOSS Team were working remotely during the ongoing pandemic. We therefore asked all reporters to complete editable pdf versions of the forms and email them back to us. This system has proved to be a great success as it has meant we haven't had to worry about forms getting delayed in various postal systems. Feedback from reporters has been positive too as they generally find it quicker and easier to complete the forms electronically. We are therefore very pleased to announce that we will be adopting this method of data collection for all other UKOSS studies, so from now on please do not post any paper data collection forms to us. If you have any questions or concerns regarding this, please do not hesitate to contact us at ukoss@npeu.ox.ac.uk.



Follow us @NPEU_UKOSS

Thank you for your continued notifications to other UKOSS studies. Below is a case summary of the non-covid studies reported up to end of June 2020.

Disorder	Actual number of reported cases	Data collection forms returned (%)	Expected number of confirmed cases
Amniotic Fluid Embolism	298	287 (65)	185
Antithrombin / Protein C deficiency	46	28 (61)	125
Bone Marrow Transplant and Pregnancy	5	2 (40)	25
Cirrhosis in Pregnancy	66	58 (88)	155
DKA	94	73 (78)	99
DKA Controls	-	230 (64)	358 Requested
EPPROM	307	187 (61)	310
Fontan and Pregnancy	21	11 (52)	29
Hyponatraemia in Pregnancy	109	74 (68)	200
New Therapies for Influenza	6	6 (100)	25

Monthly Reports

We appreciate that routine reporting may well have been delayed in some units as many of you have been prioritising Covid-19 research or haven't had the capacity to dedicate time to reporting, however we would be grateful if you could now begin to look at catching up with reporting. If you have any questions regarding outstanding reports (or indeed data collection forms) then please contact us at ukoss@npeu.ox.ac.uk.



GMC Revalidation and NMC Continuing Professional Development



We are aware that as part of your GMC revalidation or NMC Continual Professional Development, you are required to provide evidence of participation in national audit and research. If any UKOSS reporters would like to receive a certificate confirming their contribution to UKOSS, please email us at ukoss@npeu.ox.ac.uk and we will get one posted out to you.



Admin team: 01865 289714

Email: UKOSS@npeu.ox.ac.uk Web: www.npeu.ox.ac.uk/UKOSS



Studies are additionally funded by Action Medical Research & Borne, Borne, Glaxo Smith Kline via OXON Epidemiology, NIHR, NIHR Research for Patient Benefit Programme, OAA, Oxford Centre for Haematology and Biomedical Research Centre Haematology Thame, The Lauren Page Trust and Wellbeing of Women.